Mersana Therapeutics, Inc.: operating cash flow

What this measure means

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Exact concept: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2015-01-01 to 2024-12-31. The SEC response was captured on 2026-09-21.

Selected filing history

Related financial histories

• Mersana Therapeutics, Inc.: total assets
• Mersana Therapeutics, Inc.: total liabilities
• Mersana Therapeutics, Inc.: stockholders equity
• Mersana Therapeutics, Inc.: cash and cash equivalents
• Mersana Therapeutics, Inc.: net income or loss
• Mersana Therapeutics, Inc.: capital expenditure payments
• Mersana Therapeutics, Inc.: revenue
• Mersana Therapeutics, Inc.: contract revenue excluding tax
• Mersana Therapeutics, Inc.: financing cash flow
• Mersana Therapeutics, Inc.: investing cash flow
• Mersana Therapeutics, Inc.: retained earnings or deficit
• Mersana Therapeutics, Inc.: basic weighted-average shares
• Mersana Therapeutics, Inc.: diluted weighted-average shares
• Mersana Therapeutics, Inc.: basic earnings per share
• Mersana Therapeutics, Inc.: diluted earnings per share
• Mersana Therapeutics, Inc.: income tax expense or benefit
• Mersana Therapeutics, Inc.: net property, plant and equipment
• Mersana Therapeutics, Inc.: share-based compensation expense
• Mersana Therapeutics, Inc.: current assets
• Mersana Therapeutics, Inc.: interest expense
• Mersana Therapeutics, Inc.: current liabilities
• Mersana Therapeutics, Inc.: current accounts payable
• Mersana Therapeutics, Inc.: net current accounts receivable
• Mersana Therapeutics, Inc.: operating expenses
• Mersana Therapeutics, Inc.: research and development expense
• Mersana Therapeutics, Inc.: common shares outstanding
• Mersana Therapeutics, Inc.: cash including restricted cash
• Mersana Therapeutics, Inc.: accumulated other comprehensive income or loss
• Mersana Therapeutics, Inc.: operating lease right-of-use asset
• Mersana Therapeutics, Inc.: operating lease liability
• Mersana Therapeutics, Inc.: gross property, plant and equipment
• Mersana Therapeutics, Inc.: accumulated depreciation on property, plant and equipment
• Mersana Therapeutics, Inc.: other noncurrent assets
• Mersana Therapeutics, Inc.: other noncurrent liabilities
• Mersana Therapeutics, Inc.: accrued current liabilities
• Mersana Therapeutics, Inc.: prepaid expenses and other current assets
• Mersana Therapeutics, Inc.: current contract liabilities
• Mersana Therapeutics, Inc.: net deferred tax assets
• Mersana Therapeutics, Inc.: pre-tax income or loss from continuing operations
• Mersana Therapeutics, Inc.: profit or loss including noncontrolling interests
• Mersana Therapeutics, Inc.: comprehensive income or loss
• Mersana Therapeutics, Inc.: net income available to common stockholders
• Mersana Therapeutics, Inc.: general and administrative expense
• Mersana Therapeutics, Inc.: depreciation expense
• Mersana Therapeutics, Inc.: depreciation, depletion and amortization
• Mersana Therapeutics, Inc.: nonoperating interest expense
• Mersana Therapeutics, Inc.: nonoperating income or expense
• Mersana Therapeutics, Inc.: interest paid, net
• Mersana Therapeutics, Inc.: operating lease payments
• Mersana Therapeutics, Inc.: change in accounts receivable
• Mersana Therapeutics, Inc.: change in accounts payable

Inspect the source

Entity

Mersana Therapeutics, Inc. / CIK 0001442836

Captured

2026-09-21T17:19:06.893Z

SEC response SHA-256

e23cfdb1ac36facb6d0328329e147d7bf612bf4e43d42241b5307d096dd3d0bd

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001442836.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))